BeiGene launches $650m ADS follow-on

Jonathan Breen

January 17, 2018 06:15 am

Allergen_Pills_Pharma_23May2017_Fotolia_230x150

Chinese biopharmaceutical company BeiGene is looking to raise about $650m from a follow-on offering of American Depository Shares (ADSs), according to a filing with the US regulator.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login

Topics

Equity China Americas Asia Follow-ons and Rights Issues Asia Greater China Morgan Stanley Northeast Asia Asia Pacific United States Follow-ons and Rights issues Emerging Markets North America Goldman Sachs

JB

Jonathan Breen

Equities editor GlobalCapital Asia